MONDELEZ INTERNATIONAL INC Common Stock vs 22nd Century Group Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.09 (market cap $77.37B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 51926.2× 22nd Century Group Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| MDLZ | XXII | |
|---|---|---|
Market Cap | $77.37B | $1.49M |
Sector | Consumer Staples | Technology |
52-Week High | $70.75 | $1.07K |
52-Week Low | $51.51 | $3.90 |
Enterprise Value | $97.46B | -$6.74M |
Dividend Yield | 3.32% | — |
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.15, down 1.39% today, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 28.77% gross margins and has beaten earnings estimates for three consecutive quarters. Recent corporate developments include a new CFO appointment and continued dividend payments, while analyst consensus remains strongly positive with a $68 price target representing 13% upside potential.
The outlook for MDLZ appears favorable with consistent earnings beats and solid dividend yield, though investors face risks from margin compression and commodity price volatility. Wall Street's bullish stance is supported by the company's market leadership in snacks and innovation pipeline, but execution on volume growth remains critical for sustained performance.
XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.
While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.
Trailing returns across standard periods
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →